Cyclacel Pharmaceuticals (NASDAQ: ) just reported results for the third quarter of 2023. InvestorPlace Earnings is a project that leverages data from…
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cyclacel Pharmaceuticals Stock Scheduled to Reverse Split on Monday, December 18th (NASDAQ:CYCC) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note released on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock. Cyclacel Pharmaceuticals Stock Performance CYCC stock opened at $0.27 on Friday. The company’s 50 day moving average price is $0.44 and its 200 day […]